Systemic exposure and urinary cortisol effects of fluticasone propionate formulated with hydrofluoroalkane in 4- to 11-year-olds with asthma

Journal of Clinical Pharmacology

Volumn 48, Issue 1, 2008, Pages 108-116

  Kim, Kenneth T ^a   Milgrom, Henry ^b   Kellie Yoon, Y ^a   Levy, Arden L ^c   Matz, Paul ^d   Welch, Michael J ^e   Cahn, Anthony ^f   Collins, David A ^g   Kathman, Steven ^g   Mehta, Rashmi ^g   Su, Sheng Fang ^g   Kunka, Robert L ^g  

^a West Coast Clinical Trials LLC   (United States)

^b NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

^c Spartanburg Pharmaceutical Research ^*  (United States)

^d Medford Clinic   (United States)

^e ALLERGY AND ASTHMA MEDICAL GROUP AND RESEARCH CENTER   (United States)

^f GLAXOSMITHKLINE   (United Kingdom)

^g GLAXOSMITHKLINE   (United States)

Author keywords

Asthma; Children; Fluticasone; Systemic effects; Urinary cortisol

Indexed keywords

CHLOROFLUOROCARBON; FLUORINATED HYDROCARBON; FLUTICASONE PROPIONATE; HYDROCORTISONE; SALBUTAMOL;

ABSENCE OF SIDE EFFECTS; AREA UNDER THE CURVE; ARTICLE; ASTHMA; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; FEMALE; HEADACHE; HUMAN; HYDROCORTISONE URINE LEVEL; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; MAJOR CLINICAL STUDY; MALE; METERED DOSE INHALER; NAUSEA; OUTCOME ASSESSMENT; PEAK EXPIRATORY FLOW; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; URINARY EXCRETION;

ADMINISTRATION, INHALATION; AEROSOL PROPELLANTS; ANDROSTADIENES; ANTI-ASTHMATIC AGENTS; AREA UNDER CURVE; ASTHMA; CHILD; CHILD, PRESCHOOL; CHLOROFLUOROCARBONS; COUGH; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FEVER; HALF-LIFE; HEADACHE; HUMANS; HYDROCARBONS, FLUORINATED; HYDROCORTISONE; MALE; METERED DOSE INHALERS; NAUSEA; RESPIRATORY TRACT INFECTIONS;

EID: 37349038339     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270007309704     Document Type: Article

References (24)

1. Bloom B., Dey AN Summary health statistics for U.S. children: National Health Interview Survey, 2004. Vital Health Stat 10. 2006, No 227. http://www.cdc.gov/nchs/data/series/sr_10/sr10_227.pdf. Accessed May 11, 2007.
2. National Asthma Education and Prevention Program. Executive Summary of the NAEPP Expert Panel Report: Guidelines for the Diagnosis and Management of Asthma: Update on Selected Topics 2002 (NIH publication 02-5075). Bethesda, Md: US Department of Health and Human Services, National Institutes of Health ; June 2002.
3. Practical guideline for the diagnosis and management of asthma. In: Clinical Practice Guidelines of the American Academy of Pediatrics: A Compilation of Evidence-Based Guidelines for Pediatric Practice. 2 nd ed. Elk Grove Village, Ill: American Academy of Pediatrics ; 1999: 3-70.
4. Global Initiative for Asthma. Pocket Guide for Asthma Management and Prevention. Based on the Workshop Report: Global Strategy for Asthma Management and Prevention (NIH publication 02-3659). Bethesda, Md: National Institutes of Health ; 2002.
5. Flovent (fluticasone propionate) [package insert]. Research Triangle Park, NC: GlaxoSmithKline ; January 2007.
6. Lyttle B., Gilles J., Panov M., et al. Fluticasone propionate 100 μg BID using a non-CFC propellant, HFA 134a, in asthmatic children. Can Respir J. 2003 ; 10: 103-109.
7. Stone D., Mairs M., Willits L., Sharma R. A comparison of fluticasone propionate, 100μg twice daily, administered via a CFC and non-CFC propellant, HFA 134a, in adult patients with asthma. Clin Drug Invest. 2001 ; 21: 695-703.
8. Ayres JG, Millar AB, Sykes AP Clinical efficacy and safety of fluticasone propionate 1 mg twice daily administered via a HFA-134a pressurized metered dose inhaler to patients with severe asthma. Respir Med. 2000 ; 94 (suppl B): S42 - S50.
9. Tonnel AB, Bons J., Legendre M., et al. Clinical efficacy and safety of fluticasone propionate 250 mcg twice daily administered via a HFA-134a pressurized metered dose inhaler to patients with mild to moderate asthma. Respir Med. 2000 ; 94 (suppl B): S29 - S34.
10. Perruchoud AP, Lundback B., Yigla M., et al. Clinical efficacy and safety of fluticasone propionate 1 mg per day administered via a HFA-134a pressurized metered-dose inhaler to patients with moderate to severe asthma. Respir Med. 2000 ; 94 (suppl B): S35 - S41.
11. Harrison L., Soria I., Cline A., Ekholm B. Pharmacokinetic differences between chlorofluorocarbon and chlorofluorocarbon-free metered dose inhalers of beclomethasone dipropionate in adult asthmatics. J Pharm Pharmacol. 1999 ; 51: 1235-1240.
12. Busse W., Brazinsky S., Jacobson K., et al. Efficacy response of inhaled beclomethasone dipropionate in asthma is proportional to dose and is improved by formulation with a new propellant. JACI. 1999 ; 104: 1215-1222.
13. Kunka R., Andrews S., Pimazzoni M., et al. Dose proportionality of fluticasone propionate from hydrofluoroalkane pressurized metered dose inhalers (pMDIs) and comparability with chlorofluorocarbon pMDIs. Respir Med. 2000 ; 94 (suppl. B): S10 - S16.
14. American Thoracic Society (ATS). Standards for the diagnosis and care of subjects with chronic obstructive pulmonary disease (COPD) and asthma. Am Rev Respir Dis. 1987 ; 136: 225-244.
15. Polgar G., Promadhat V. Pulmonary Function Testing in Children: Techniques and Standards. 1 st ed. Philadelphia, Pa: Saunders ; 1971.
16. Callejas SL, Biddlecombe RA, Jones AE, Joyce KB, Pereira AI, Pleasance S. Determination of the glucocorticoid fluticasone propionate in plasma by automated solid-phase extraction and liquid chromatography-tandem mass spectrometry. J Chromatography B. 1998 ; 718: 243-250.
17. Bessmertny O., Liang J., Hochhaus G., Chesrown S., Hendeles L. Fluticasone plasma concentrations in children with asthma after delivery by MDI. J Pediatr Pharmacol Ther. 2001 ; 6: 212-217.
18. Malone R., LaForce C., Nimmagadda S., et al. The safety of twice-daily treatment with fluticasone propionate and salmeterol in pediatric patients with persistent asthma. Ann Allergy Asthma Immunol. 2005 ; 95: 66-71.
19. Kunka RL, Andrews S., Wang Y., Mehta R., Daley-Yates PT Low fluticasone propionate exposure and effects on cortisol for CFC-free metered dose inhalers in healthy subjects and asthmatics. J Allergy Clin Immunol. 2004 ; 113 (suppl 1). S117.
20. Boles MG, Cripps AL The pharmaceutical evaluation of the new HFA-134a metered dose inhaler (MDI) formulations of fluticasone propionate. Eur Respir J. 1999 ; 14 (suppl 30). 341S.
21. Cripps A., Riebe M., Schulze M., Woodhouse R. Pharmaceutical transition to non-CFC pressurized metered dose inhalers. Respir Med. 2000 ; 94 (suppl B): S3 - S9.
22. Leach C., Davidson P., Boudreau R. Improved airway targeting with the CFC-free HFA-beclomethasone metered-dose inhaler compared with CFC-beclomethasone. Eur Respir J. 1998 ; 12: 1346-1353.
23. Levy AL, Given JT, Weinstein SF, et al. Efficacy and safety of fluticasone propionate hydrofluoralkane inhalation aerosol in 4 to 11 year old children with asthma: a randomized double-blind placebo-controlled study. Pediatr Asthma Allergy Immunol. 2006 ; 19: 106-117.
24. Peden DB, Berger WE, Noonan MJ, et al. Inhaled fluticasone propionate delivered by means of two different multidose powder inhalers is effective and safe in a large pediatric population with persistent asthma. J Allergy Clin Immunol. 1998 ; 102: 32-38.